References
- 1. Kristensen SD, Knuuti J, Saraste A et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2014;31(10):517-73.10.1097/EJA.000000000000015025127426
- 2. 2014 ESC/ESA Guidelines on non-cardiac surgery:cardiovascular assessmeny and management, European Heart Journal, 2014.
- 3. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.10.1056/NEJMoa090556119717844
- 4. Go AS, Singer DE, Toh S et al. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Ann Intern Med. 2017;167(12):845-854.10.7326/M16-115729132153
- 5. Connolly SJ, Wallentin L, Yusuf S. Additional events in the RE-LY trial. N Engl JMed. 2014;371(15):1464-5.10.1056/NEJMc140790825251519
- 6. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl JMed. 2011;365(11):981-92.10.1056/NEJMoa110703921870978
- 7. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl JMed. 2011;365(8):699-708.10.1056/NEJMoa110581921780946
- 8. Korjian S, Braunwald E, Daaboul Y et al. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarkerpositive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. 2017:2048872617745003.10.1177/204887261774500329249166
- 9. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.10.1056/NEJMoa100963821830957
- 10. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104.10.1056/NEJMoa131090724251359
- 11. Siegal DM, Curnutte JT, Connolly SJ et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl JMed. 2015;373(25):2413-24.10.1056/NEJMoa151099126559317
- 12. Ansell JE, Bakhru SH, Laulicht BE et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141-2.10.1056/NEJMc1411800
- 13. Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. AmJ Emerg Med. 2016;34(11S):26-32.10.1016/j.ajem.2016.09.050
- 14. Choo WK, Fraser S, Padfield G et al. Dabigatran improves the efficiency of an elective direct current cardioversion service. Br J Cardiol 2014;21:29–32.
- 15. Cappato R, Ezekowitz MD, Klein AL et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55.10.1093/eurheartj/ehu367
- 16. Sakabe M, Yoshioka R, Fujiki A. Low APTT and BMI predicts the occurrence of ischemic stroke in patients with Atrial Fibrillation receiving Dabigatran, JACC 2014; 63(12):A1436.10.1016/S0735-1097(14)61436-4
- 17. Burnett A, Siegal D, Crowther M. Specific antidotes for bleeding associated with direct oral anticoagulants. BMJ. 2017;357:j2216.10.1136/bmj.j221628546438
- 18. Heidbuchel H, Verhamme P, Alings M, et al. Advisors. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2016;9:ehw058.10.1093/eurheartj/ehw058583723127282612
- 19. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016;41:206-32.10.1007/s11239-015-1310-7471584826780747
- 20. Nafee T, Aslam A, Chi G et al. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. Expert Rev Cardiovasc Ther. 2017;15(4):237-245.10.1080/14779072.2017.130588928282497
- 21. Burnett A, Siegal D, Crowther M. Specific antidotes for bleeding associated with direct oral anticoagulants. BMJ 2017;357:j221610.1136/bmj.j2216